BACKGROUND: PCTP (phosphatidylcholine transfer protein) regulates the intermembrane transfer of phosphatidylcholine. Higher platelet PCTP expression is associated with increased platelet responses on activation of protease-activated receptor 4 thrombin receptors noted in black subjects compared with white subjects. Little is known about the regulation of platelet PCTP. Haplodeficiency of RUNX1, a major hematopoietic transcription factor, is associated with thrombocytopenia and impaired platelet responses on activation. Platelet expression profiling of a patient with a RUNX1 loss-of-function mutation revealed a 10-fold downregulation of the PCTP gene compared with healthy controls.
A member of the steroidogenic acute regulatory protein-related transfer domain superfamily, PCTP (phosphatidylcholine transfer protein) is responsible for the intermembrane transfer of phosphatidylcholine, a major plasma membrane phospholipid. PCTP has a wide tissue distribution 1 and is abundantly expressed in human platelets but not in mouse platelets. 2 The specific function of PCTP in platelets or other cells is unclear, but several findings suggest that it is important for platelet function. Phosphatidylcholine constitutes a major fraction of platelet phospholipids and source of arachidonic acid on platelet activation for thromboxane production. 3, 4 Phosphatidylcholine is also a substrate for phospholipase D, leading to formation of phosphatidic acid and the second messenger diacylglycerol. 5 Pharmacological inhibition of PCTP decreased platelet aggregation in response to thrombin proteaseactivated receptor 4 (PAR4) agonist, and knockdown of PCTP in megakaryocytic cells blunted PAR4-induced calcium mobilization. 2 Platelet PCTP has been implicated in racial differences in platelet responses; increased PCTP expression has been associated with higher platelet aggregation and calcium mobilization induced by PAR4 in black subjects compared with white subjects. 2 Little is known about the regulation of PCTP expression in platelets and megakaryocytes.
RUNX1 is a major hematopoietic transcription factor and regulates numerous megakaryocytic/platelet genes. 6, 7 RUNX1 expression is known to initiate at 2 alternative promoters, a distal P1 and a proximal P2 promoter, which, together with alternative splicing, results in different isoforms of RUNX1 protein that have distinct roles and tissue expression. [8] [9] [10] [11] [12] [13] [14] [15] Two isoforms, variant 1 (NM_001754) and variant 2 (NM_001001890.1), expressed from the P1 and P2 promoters encode for RUNX1 proteins of 480 and 453 amino acids, respectively ( Figure I in the online-only Data Supplement). Variants 1 and 2 differ in their exons 1 but otherwise share the remaining RUNX1 exons. Platelets (D.V. and A.K.R., unpublished data, 2017) and human erythroleukemia (HEL) cells 16 express both variants. Human RUNX1 haplodeficiency is associated with thrombocytopenia, platelet function defects, and increased risk of leukemia and myelodysplastic syndromes. 17, 18 The platelet abnormalities described include diminished aggregation and granule secretion, protein phosphorylation (pleckstrin and myosin), and activation of glycoprotein IIb/IIIa complex on activation. 18, 19 Expression profiling of platelets from a patient we described previously with a heterozygous RUNX1 nonsense mutation 20 showed a marked downregulation of PCTP expression (fold change ratio, 0.09; P=0.02) compared with normal control subjects. 21 These studies also showed that several other genes were significantly downregulated, including MYL9, PF4, PRCKQ, ALOX12, and PLDN; we have shown that these are transcriptionally regulated by RUNX1. 20, [22] [23] [24] [25] [26] On the basis of the decreased platelet PCTP expression in our patient with RUNX1 haplodeficiency 21 and the association between PCTP and enhanced platelet responses, 2 we hypothesized that PCTP is regulated by RUNX1. Our results provide the first evidence that PCTP is a direct transcriptional target of RUNX1, constituting a cogent mechanism for downregulation of platelet PCTP in our patient. To reinforce the hypothesis that RUNX1 regulates PCTP, we evaluated peripheral blood gene expression correlation for RUNX1 and PCTP and report strong correlation. To assess the potential clinical relevance, we assessed the relationship between PCTP in blood and clinical events in 2 separate cohorts of patients with cardiovascular disease from the Duke Catheterization Genetics (CATHGEN) cohort we have previously studied. 27 These studies revealed that PCTP expression is independently associated with death or myocardial infarction (MI) in patients with cardiovascular disease.
Clinical Perspective
What Is New?
• Phosphatidylcholine transfer protein (PCTP) regulates intermembrane transfer of phosphatidylcholine. Platelet PCTP expression is associated with increased platelet responses on activation of protease-activated receptor 4 thrombin receptors noted in black subjects. Little is known about regulation of platelet PCTP.
• Our studies showed that PCTP is a direct transcriptional target of RUNX1, a major hematopoietic transcription factor that regulates platelet production and function.
• Our studies in patients with cardiovascular disease showed that PCTP expression in blood correlates with RUNX1 expression and was independently associated with future death/myocardial infarction.
What Are the Clinical Implications?
• Platelet PCTP has been shown to regulate platelet responses on activation with protease-activated receptor 4 thrombin receptors.
• Our studies identify a novel association between PCTP expression in blood and death/myocardial infarction in patients with cardiovascular disease and suggest that regulation of PCTP by transcription factor RUNX1 may play a role in the pathogenesis of platelet-mediated cardiovascular events.
• Our findings implicate PCTP as a novel gene in the pathogenesis of myocardial infarction and motivate novel biomarkers and therapeutics to prevent myocardial infarction.
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METHODS
Patient With RUNX1 Haplodeficiency
We have previously described 19, 21 the clinical presentation and studies in this 38-year-old white man, documenting decreased agonist-stimulated platelet aggregation, secretion, glycoprotein IIb/IIIa activation, and phosphorylation of pleckstrin and myosin light chain; his platelet protein kinase C-θ level was also decreased. This patient was initially referred for evaluation of easy bruising and epistaxis. The patient has a single point mutation in RUNX1, in intron 3 at the splice acceptor site for exon 4, leading to a frameshift with premature termination in the conserved Runt homology domain. 20 This research in the patient with RUNX1 haplodeficiency and healthy subjects was approved by the institutional human subjects review board of Temple University, and all participants gave written informed consent.
Patient Cohorts With Cardiovascular Disease
The CATHGEN cohort is a sequential cohort of patients presenting to the Duke University Medical Center cardiac catheterization laboratory who provided informed consent for biological specimen banking. CATHGEN consists of 2 cohorts of patients with cardiovascular disease, an observational and a case/control cohort. The baseline clinical, medication, microarray data generated from unfractionated peripheral blood RNA preserved in PAXgene collection tubes at the time of catheterization, and long-term clinical outcomes from the CATHGEN cohorts have been described. 27 All CATHGEN participants provided informed consent, and this analysis was approved by the Duke University Medical Center institutional review board.
Materials
The RUNX1 siRNA, PCTP siRNA, control siRNA, and antibodies against RUNX1, PCTP, and β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Phorbol 12-myristate 13-acetate (PMA) was from Enzo Life Sciences (Farmingdale, NY). Luciferase Reporter Assay System kit, polymerase chain reaction (PCR) reagents, PGL3-basic vector, and the Renilla luciferase control vector were purchased from Promega Biotech (Madison, WI). Trizol reagent was from Life Technologies Corp (Carlsbad, CA). All oligonucleotides and IRDye-labeled probes were synthesized by Integrated DNA Technologies (Coralville, IA). Fluorophore-conjugated secondary antibodies raised in donkey were from Jackson ImmunoResearch Laboratories (West Grove, PA).
Computational Bioinformatics
Potential transcription factor RUNX1 binding sites were predicted by use of TFsearch and TFBIND INPUT (http://www. cbrc.jp/research/db/TFSEARCH.html, http://tfbind.hgc.jp/).
Preparation of Platelet RNA and Proteins
Whole-blood samples were collected from the patient and healthy volunteer donors into 7.5 mL each of acid citrate dextrose solution (71.4 mmol/L citric acid, 85 mmol/L sodium citrate-dihydrate, 11.1 mmol/L dextrose) as described previously. 19, 20 The platelet pellet was washed twice in Hepes buffer (pH 6.5; 20 mmol/L Hepes, 5.5 mmol/L dextrose, 0.376 mmol/L NaH 2 PO 4 , 1 mmol/L MgCl 2 2.7 mmol/L KCl, 137 mmol/L NaCl and 1 mg/mL BSA) and resuspended in TRIzol Reagent (Life Technologies) for total RNA isolation as recommended by the manufacturer. For preparing platelet protein, pellets were resuspended in M-Per Mammalian Protein Extraction Reagent (ThermoFisher Scientific, Grand Island, NY) with proteinase inhibitors.
Cell Cultures
HEL cells obtained from the American Type Culture Collection (Rockville, MD) were cultured in RPMI 1640 medium (Mediatech, Manassas, VA) supplemented with 10% FBS (GE Healthcare, Mississauga, ON, Canada) and penicillin (100 U/ml)/streptomycin (100 mg/mL) (Invitrogen, Carlsbad, CA) at 37°C in a humidified 5% CO 2 atmosphere. HEL cells were treated with PMA (10-30 nmol/L) for 24 hours to induce megakaryocytic transformation.
Chromatin Immunoprecipitation Assays
HEL cells treated with PMA (10 nmol/L) were cross-linked with 1% formaldehyde. Chromatin immunoprecipitation analysis was performed with the Active Motif ChIP-IT assay kit (Carlsbad, CA). Chromatin was immunoprecipitated with control IgG from the Active Motif and anti-RUNX1 antibodies (Santa Cruz; catalog No. sc-8563). PCR reactions were performed with the primers listed in Table I in the online-only Data Supplement. PCR products were analyzed by electrophoresis on 3% agarose gels.
Nuclear Extract Preparation and Electrophoretic Mobility Shift Assay
Nuclear protein was extracted from PMA (10 nmol/L)-treated HEL cells with NE-PER Nuclear and Cytoplasmic Extraction Reagents (ThermoFisher Scientific). IRDye-labeled oligonucleotides were double stranded. Electrophoretic mobility shift assay was done with the Odyssey Infrared EMSA Kit (Li-Cor Biosciences, Lincoln, NE). Nuclear protein (10 µg) was incubated (20 minutes, room temperature) with 50 nmol/L probe and 1 µg Poly(deoxyinosinic-deoxycytidylic) in a 20-µL reaction including 10 mmol/L Tris, pH 7.5, 50 mmol/L KCl, 3.5 mmol/L DTT, 0.25% Tween 20, 2.5% glycerol, and 10 mmol/L EDTA. For supershift assays, 1 µg anti-RUNX1 antibodies (Santa Cruz; catalog No. sc-8563) or control IgG (Santa Cruz) were incubated with the binding reaction (20 minutes, room temperature). Competition assays were performed with 100-fold excess unlabeled probe. Binding complexes were separated by electrophoresis on 5% Tris-borate-EDTA native acrylamide gels (Bio-Rad Laboratories) at 4°C and imaged with the Odyssey Infrared Imaging System (Li-Cor Biosciences). The oligonucleotide sequences used to prepare DNA probes are shown in Table II in the online-only Data Supplement.
Promoter and Plasmid Construction
Genomic DNA was isolated from human blood with the Genomic DNA isolation kit (Qiagen). The promoter region of PCTP was obtained by PCR amplification of the genomic DNA (primers listed in Table III in the online-only Data Supplement). Promoter-luciferase constructs were generated with DNA fragments containing human PCTP promoter regions −1015 to −3 and −106 to −3 (from ATG) and cloned into the PGL3-basic vector (Promega). The constructs with RUNX1 sites mutated were generated with the QuikChange Site-Directed Mutagenesis Kit (Stratagene Inc, La Jolla, CA; Table III in 
Cell Extracts and Immunoblotting
Western blot analysis was performed on cells lysed in M-PER Mammalian Protein Extraction Reagent (ThermoFisher Scientific) with protease inhibitors (Enzo Life Sciences). Lysates (20 or 30 µg) were subjected to 10% or 12% SDS-PAGE and transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA). Blots were probed with the antibodies against RUNX1, PCTP, and β-actin (Santa Cruz). The secondary antibodies were IRDye-labeled antibodies (Li-Cor Biosciences). Immunoreactive proteins were detected with the Odyssey Infrared Imaging system (Li-Cor Biosciences). 
Effect of RUNX1 Overexpression on PCTP Expression
These studies were performed with the expression plasmid RUNX1-pCMV6-XL4 and empty pCMV6-XL4 vector (OriGene Technologies, Rockville, MD). This plasmid expresses RUNX1 variant 2 (NM__001001890), expressed from RUNX1 P2 promoter. HEL cells were transiently cotransfected with Lipofectamine 2000 (Invitrogen) with 100 ng-650 ng RUNX1-pCMV6-XL4 plasmid or empty vector and PCTP promoter luciferase reporter constructs (−1015/PGL3-basic). The cells were harvested 24 to 48 hours for luciferase activity, immunoblotting, or RNA extraction.
Immunostaining and Microscopy
Glass coverslips were incubated (4°C overnight) with 5 µg/ mL plasma fibronectin; after washing, the coverslips or slides were incubated for 30 minutes with heat-inactivated 1% BSA/PBS. Cells were seeded on the coated coverslips for 1 hour at 37°C. Adherent cells were fixed in 3.7% formaldehyde/PBS for 20 minutes at room temperature. Fixed cells were washed and permeabilized with 0.1% Triton X-100/PBS for 5 minutes, washed with PBS, incubated with primary antibodies for 1 hour at room temperature, washed, and then incubated with fluorophore-conjugated secondary antibodies, followed by nuclear staining with 30 nmol/L DAPI for 10 minutes. Fluorophores used were FITC and Cy3 (Jackson ImmunoResearch). Coverslips were washed and mounted on slides with ProLong Gold antifade reagent (Invitrogen). Cells were imaged with a Leica DM IRE2 microscope with a TCS SL confocal system using a 63×/1.40 NA oil-immersion objective at room temperature and Leica imaging software or on a Nikon E800 using a 63×/1.40 NA oil-immersion objective at room temperature and Q-Capture software. Confocal images were captured by line sequential scanning using 4× line averaging and 3× frame averaging at 400-Hz scan speed. Postacquisition image processing was performed with ImageJ and Adobe Photoshop. Operations included brightness/contrast adjustment to all pixels in the images and grouping of images. Fluorescence intensity analysis was performed with ImageJ and Microsoft Excel. Corrected total cellular fluorescence was calculated as the average of individual cell fluorescence intensities divided by the single cell area, >100 cells per sample.
Statistical Analysis for In Vitro Studies
Results of the in vitro studies are expressed as mean±SEM. Differences were compared by use of the Student t test.
Statistical Analysis of Data From the CATHGEN Study
Microarray gene expression data were normalized with Robust Multiarray Average separately for the 2 cohorts making up the CATHGEN study: observational (n=190) and case/control (n=397) as previously described. 27 To assess for correlation between RUNX1 and PCTP expression, we used microarray data from CATHGEN participants. Several potential probe sets available on the Affymetrix microarray map to the RUNX1 locus on chromosome 21. Of the 17 available probe sets, ORIGINAL RESEARCH ARTICLE we selected 6 that map to a single locus in the genome and had evidence by PCR for being able to discriminate between RUNX1 P1 and P2 expression by PCR (Table V in the onlineonly Data Supplement) as previously described. 16, 27 To select microarray probe sets for RUNX1, we used banked, serial peripheral blood RNA from healthy volunteers with matched microarray data 27 and performed PCR for RUNX1 isoforms. 16 Linear mixed-effects regression with a random effect for subject was used to model the linear relationship between RUNX1 probe set expression and RUNX1 PCR expression. Effect sizes, standard errors, and P values (calculated with a normal approximation) are reported. Correlation between PCTP and the selected RUNX1 probe sets was evaluated with linear regression, including age, sex, and race covariates. Race-stratified PCTP-RUNX1 correlations were similarly tested. Both global and within-race correlations were combined across studies by inverse variance weight meta-analysis. PCTP was tested for differential expression resulting from race with a moderated t test, 28 and the log-fold changes were combined across studies with the use of inverse variance-weighted meta-analysis.
To assess for the association between PCTP expression and cardiovascular events, we used longitudinal follow-up data from CATHGEN participants. In each cohort, the PCTP probe set (218676_s_at) was tested for effects on MI or death events with logistic regression. Two covariate models were evaluated: the reduced covariate model controlling for the effects of age, sex, and race on death or MI outcomes and the full covariate model controlling for the effects of age, sex, race, smoking status, body mass index, hyperlipidemia, hypertension, diabetes mellitus, platelet count, aspirin treatment, and aspirin-response signature genes (ARS) 27 previously shown to correlate with death/MI outcomes in these cohorts. Meta-analysis was used to combine evidence of PCTP probe expression on the cumulative incidence of death or MI in each cohort. For each probe, the log odds ratios (ORs) and their standard errors were pooled as the weighted average of the log ORs with the use of inverse variance weights, assuming a fixed-effect model The log-fold change of PCTP expression associated with death/MI was estimated with linear regression, modeling PCTP expression as response to death or MI outcome and adjusting for age, sex, and race.
All CATHGEN data processing and statistical analyses were conducted in R version 3.2 (http://www.r-project.org/) with the affy, meta, and limma packages for normalization, metaanalyses, and moderated t tests, respectively.
RESULTS
Platelet PCTP Expression Is Decreased in the Patient With RUNX1 Haplodeficiency
In previously reported expression profiling studies using Affymetrix U133 Gene Chips, 21 platelet PCTP expression was decreased in the patient (2 separate studies) compared with profiles from 6 healthy control subjects (fold change=0.1=; P=0.028). This was validated with quantitative PCR; the platelet mRNA in the patient was lower than in 5 healthy subjects matched for race ( Figure 1A) . Immunofluorescence studies using anti-PCTP antibodies, performed on 2 separate occasions, showed that the corrected total cellular fluorescence was reduced by ≈50% in patient platelets compared with platelets from 4 matched control subjects, indicating decreased PCTP protein.
Results from the patient and 3 control subjects studied concurrently are shown ( Figure 1B ).
RUNX1 Binds to PCTP Promoter Region In Vivo
Analysis in silico with the TFBIND database revealed 5 RUNX1 consensus binding sites within 1000 base pairs (bps) of the PCTP 5′ upstream region from ATG (Figure 2A 
RUNX1 Binds PCTP Promoter Sequences
Electrophoretic mobility shift assay studies using nuclear extracts from PMA-treated HEL cells showed RUNX1 binding to probe containing site 1 and the probe with both sites 4 and 5 ( Figure 2C ) but not probes with sites 2 or 3 (data not shown). In studies with the probe containing site 1, there was protein binding ( Figure 2C 
RUNX1 Binding Sites Have Promoter Activity
In luciferase reporter studies in HEL cells, mutation of each of RUNX1 binding sites 1 to 5 in the PCTP promoter resulted in ≈50% reduction in promoter activity ( Figure 2D ), indicating that these sites were functional. Together, the concordant results of the chromatin immunoprecipitation, electrophoretic mobility shift assay, and luciferase reporter studies suggest that RUNX1 in-teracts with the PCTP 5′ upstream region through consensus sites 1, 4, and 5 and regulates promoter activity.
RUNX1 Overexpression and RUNX1 siRNA Inhibition Modulate PCTP Expression
Overexpression of RUNX1 variant 2 in HEL cells showed an increase in RUNX1 protein (Figure 3 ). There was an increase in PCTP promoter activity, mRNA, and protein ( Figure 3A ). RUNX1 downregulation with non-variant selective siRNA decreased expression of RUNX1 and PCTP mRNA and protein ( Figure 3B ). Staining with anti-PCTP antibodies showed ≈50% reduction in corrected total cellular fluorescence in RUNX1 siRNA-transfected cells ( Figure 3C ).
CATHGEN Cohorts: PCTP Expression in Blood Correlates With RUNX1 Expression and Cardiovascular Events
To test the validity of using PCTP expression in unfractionated whole blood as a surrogate for platelet PCTP expression, we first confirmed the differential platelet PCTP expression by race in whole-blood PCTP gene expression data from patients referred for coronary angiography. We found that in 2 separate CATHGEN cohorts (Table VI in the online-only Data Supplement), PCTP expression was higher in blacks (log-fold change for PCTP expression in black versus white subjects in observational cohort, 0.66; 95% confidence interval [CI], 0.42-0.91; P≤0.0001; case/control cohort, 0.16; 95% CI, 0.01-0.34; P=0.07). In addition, we found a significant correlation between peripheral blood and platelet PCTP (Spearman ρ=0.22, P=0.002; D.V., unpublished, 2017). On the basis of this finding and a consistently higher peripheral blood PCTP expression in blacks versus whites, we used whole-blood PCTP expression as a surrogate for platelet PCTP expression.
RUNX1 expression initiates at 2 alternative promoters, a distal P1 and a proximal P2 promoter that encode for variants 1 and 2, respectively. [8] [9] [10] The available probe sets on the Affymetrix microarray that map to the RUNX1 locus on chromosome 21 represent transcripts that originate from both promoters ( Figure 4A ). To test the hypothesis that RUNX1 expression correlates with PCTP expression in peripheral blood RNA, we first selected 6 probe sets that uniquely mapped to the genome and had evidence by PCR for being able to discriminate between RUNX1 P1 and P2 expression by PCR (see Methods). These probe sets map to the RUNX1 region and correlate with transcripts from either P1 or P2 by PCR Figures 4B and 5) . We found that both P1 RUNX1 probe sets were negatively correlated with PCTP gene expression in each cohort and when combined ( Figure 5A and 5B and Table) and that effects were similar in blacks and whites ( Figure 4B ). With respect to P2 RUNX1 probe sets, when the cohorts were combined, only 2 of 4 probe sets had evidence for a positive correlation (P≤0.05) with PCTP expression (Figures 4B, 5E , and 5F). When analyzed separately, the relationship was positive and significant for 3 of the 4 probe sets in the observational cohort and for 2 of 4 probe sets in the case/control cohort. (Figure 5C through 5F and  Table) . Overall, although there was a clear negative correlation between RUNX1 P1 and PCTP expression, there was no consistent evidence for a relationship between RUNX1 P2 probe sets and PCTP expression.
Platelet hyperreactivity is associated with a higher risk of cardiovascular events. 29 Higher platelet PCTP expression is associated with an enhanced platelet response to PAR4 agonists. 2 Our previous studies have revealed that gene expression in peripheral blood correlates with platelet functionality. 27 To test the hypothesis that peripheral blood PCTP expression was correlated with future cardiovascular events, we used follow-up death and MI data from the 2 CATHGEN cohorts whom we previously studied. 27 We found that 
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higher PCTP expression was associated with future death/MI after adjusting for age, sex, and race across cohorts (meta-analysis OR, 2.10; 95% CI, 1.61-2.10; P<0.0001; and meta-analysis log2-fold change, 0.35; 95% CI, 0.23-0.47; P<0.0001; Figure 5G ) and was consistent within each cohort (observational cohort OR, 2.37; 95% CI, 1. 27 and platelet count and was consistent within each cohort separately: observational and case/control cohort ORs, 95% CIs, and P values were 2.16, 1.4 -3.4, and 0.0007937 and 2.01, 1.5-2.8, and 1.07e−05, respectively. Thus, higher PCTP expression is associated with a higher risk of cardiovascular events. In a separate CATHGEN analysis, 16 we previously showed that RUNX1 P1 probe sets (233690_at and 220918_at) are significantly lower in CATHGEN patients who develop death or MI. Of the RUNX1 P2 probe sets described earlier, one 211181_x_at was associated with higher risk of death/MI in CATHGEN (OR, 3.3; 95% CI, 1.5-7.3; P=0.003). Together, these findings demonstrate a consistent directionality of associations and that RUNX1 regulation of PCTP expression may be clinically relevant for the development of cardiovascular events. A, Known mRNA from the RUNX1 locus is depicted, along with its reference sequence identifier, intron/exons composition, and genomic coordinates on chromosome 21 based on hg19 human genome assembly. Solid arrows represent RUNX1 isoforms that originate from P1 and P2 promoters. Asterisks indicate approximate location of polymerase chain reaction primers used to distinguish between P1-and P2-derived isoforms. The vertical dashed line represents where the genomic coordinates on the x axis were interrupted to reduce the width of the overall image. RUNX1 variant 1 isoform (Refseq gene ID, NM_001754) and variant 2 isoform (Refseq gene ID, NM_001001890) have different exon 1 use, are expressed from the P1 and P2 promoters, and encode for proteins of 480 and 453 amino acids, respectively. Selected (see Methods for selection criteria) Affymetrix U133 probe sets aligned to the RUNX1 locus are depicted. B, Correlation of PCTP with RUNX1 expression in peripheral blood RNA. The slope of the association between expression of selected RUNX1 probe sets originating from the P1 and P2 promoters and PCTP probe set (218676_s_at) microarray expression stratified by race is shown on the y axis with the size of the points reflective of the P value and stratified by race. The data are from 2 separate cohorts (combined) from the Duke Catheterization Genetics biorepository. Slopes >0 reflect positive correlation, and those <0 reflect negative correlation.
DISCUSSION
Our studies provide the first evidence that PCTP is a direct transcriptional target regulated in platelets/ megakaryocytic cells by transcription factor RUNX1 in an isoform-dependent manner, and that blood PCTP expression is associated with future death or MI in patients with cardiovascular disease. Platelet PCTP expression was decreased in our patient with RUNX1 haplodeficiency ( Figure 1 ). Our studies provide evidence that RUNX1 binds to the PCTP promoter and that the sites have promoter activity (Figure 2 ). Overexpression of RUNX1 variant 2 increased PCTP expression (Figure 3) . RUNX1 downregulation elicited the opposite effects ( Figure 3) . These findings provide a mechanism for the decreased platelet PCTP expression in our patient with RUNX1 haplodeficiency. Previous studies showing that inhibiting PCTP blunts PAR4 agonist-stimulated platelet responses 2 suggest that decreased platelet PCTP expression may contribute to the platelet dysfunction in RUNX1 haplodeficiency. We now show also that higher PCTP expression in blood is associated with a higher risk of platelet-mediated events in patients with cardiovascular disease. Together, our findings implicate RUNX1 regulation of PCTP as a novel mechanism underlying MI.
Although PCTP has been recognized for many years, the pathways directly regulated by PCTP in various cells remain unclear. In mouse models, PCTP has been shown to play a role in lipid and glucose metabolism. 1 Human genetic polymorphisms in PCTP may modulate cardiovascular risk by influencing low-density lipoprotein size. 30 In platelets, phosphatidylcholine is a major source of arachidonic acid mobilized on platelet activation and modulates thromboxane A 2 synthesis. 3, 4 However, knockdown of PCTP in HEL cells had no effect on thromboxane production in response to agonists, including a PAR4 agonist (F.E.D.C.-C. and A.K.R., unpublished, 2017). In addition, thrombin-induced free arachidonic acid release was unaffected in 2 patients with a RUNX1 mutation identical to that of the present patient. 31 Thus, the reported effects of inhibiting PCTP on platelet responses 2 are unlikely due to decreased thromboxane production.
Edelstein et al 2 reported an association between the increased PAR4 agonist-induced platelet aggregation among healthy black subjects and increased expression of platelet PCTP. Our studies in the CATHGEN cohorts revealed higher PCTP expression in black subjects (Figure 4 ). These studies provide the first evidence that RUNX1 expression correlates with PCTP expression (Figure 5 ). We found a strong negative relationship of blood PCTP expression to RUNX1 P1 probe sets and evidence for differential regulation by P1-and P2-driven RUNX1 (Figures 4 and 5) . This divergence may be related to the biology of RUNX1. RUNX1 expression is driven by 2 promoters, the proximal P2 and distal P1 promoter, which have distinct roles and tissue expression, 9-15 influenced also by different binding partners. 11, 32 For example, during hematopoietic development from human embryonic stem cells, RUNX1 isoforms expressed from P1 and P2 promoters were differentially expressed; although total RUNX1 expression and variant 2 expression were constant throughout the differentiation process, variant 1 expression was dynamic, peaking at day 12 with a pattern similar to that of hematopoietic stem cell markers. 13 The RUNX1 variant 1 expression coincided with the emergence of definitive hematopoietic stem cells. 13 Platelets and HEL cells express both variants at mRNA and protein levels 16 (D.V. and A.K.R., unpublished, 2017). Moreover, in our unpublished studies in HEL treated with PMA to induce megakaryocytic transformation, there was decrease in RUNX1 expression from the P1 promoter with an increase in P2-driven expression. These reflect the dynamic nature of regulation from the 2 promoters. Little is known about the relative abundance and differential regulation of variant 1 or 2 in cells or the impact on target gene expression.
RUNX1 is a positive regulator for many genes and a repressor for some.
18,33 RUNX1 regulates the thrombo- 32 Moreover, RUNX1 autoregulates its gene transcription through the P1 promoter. In recent studies, 9 2 conserved RUNX1 binding sites in the P1 promoter were positive regulators, whereas 3 sites in the 5′ untranslated region were repressors. Our studies show that P1-(variant 1) and P2-(variant 2) derived RUNX1 isoforms may have differential effects in regulating PCTP (Figures 4 and 5) and on clinical events. 16 In HEL cells, RUNX1 P2-driven variant 2 was a positive regulator of PCTP (Figure 3 ), as we have also shown for other platelet/megakaryocyte genes. 18, [22] [23] [24] [25] Of note, we have previously shown 16 that in HEL cells aspirin inhibits RUNX1 P2 transcript expression and increases RUNX1 P1 expression with a decrease in the ratio of P2 to P1. This was associated with a decrease in the expression of MYL9 (myosin light chain), a known RUNX1 target. 16, 22 Overall, our studies support the premise that RUNX1 regulates the expression of PCTP and other genes through mechanisms that involve autoregulation of its own variants, in addition to differential effects of the variants on gene expression. Other evidence indicates that regulation of expression of P1 and P2 RUNX1 isoforms may be controlled by different signaling or upstream mechanisms. 34, 35 For example, Wnt/β-catenin signaling induces RUNX1 transcription by binding to a conserved region within the P1 promoter. 34 Further studies are needed to elucidate these complex mechanisms and the relative roles of RUNX1 isoforms in gene expression in megakaryocytes/platelets.
We found an association between PCTP expression and future death/MI in patients with cardiovascular disease, which persisted after adjustment for age, sex, race, cardiovascular risk factors, aspirin use, and platelet count. In studies in healthy human volunteers administered aspirin, Voora et al 27 have identified a set of 62 genes in blood (ARS) that are associated with platelet responses in in vitro platelet function testing. This ARS was associated with death/MI 27 in the CATHGEN cohort; PCTP was not one of the ARS genes. In present studies, the association of PCTP with cardiac events persisted even after adjustment for the ARS genes. Overall, these studies implicate PCTP in outcomes of cardiovascular disease.
Our studies demonstrate that PCTP is a transcriptional target of RUNX1 in megakaryocytes/platelets with direct evidence from the patient with RUNX1 haplodeficiency and the studies in platelets and megakaryocytic cells. The studies in the CATHGEN cohort were performed in unfractionated blood samples containing other cells (eg, leukocytes), which also express PCTP. In our previous studies in the CATHGEN cohorts and healthy subjects, 27 gene expression in whole blood correlated with platelet function, and the ARS identified in whole blood included many genes that are platelet derived 27 and have RUNX1 binding sites. 16 These findings indicate that gene expression in whole blood may reflect the expression of certain platelet genes. Future studies on regulation of PCTP in leukocytes may provide important insights.
CONCLUSIONS
These studies provide evidence for platelet PCTP deficiency in RUNX1 haplodeficiency and that PCTP is a direct transcriptional target of RUNX1 with a differential regulation by RUNX1 isoforms arising from the proximal and distal RUNX1 promoters. They advance an association between blood PCTP expression and major clinical events in patients with cardiovascular disease and suggest a potentially important mechanism between RUNX1, PCTP, and outcomes in cardiovascular disease.
